Multiple drug resistance in osteosarcoma.

R N Rosier, L A Teot, D G Hicks, C Schwartz, R J O'Keefe, J E Puzas

Abstract read

In one paragraph

Article in The Iowa orthopaedic journal, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it

0cells of the map it votes in

4citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo.Frontiers in pharmacology · 2021
Article
Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.Molecular and clinical oncology · 2016
Article
High expression of MACC1 predicts poor prognosis in patients with osteosarcoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
Article
In situ hybridization in the pathology laboratory: general principles, automation, and emerging research applications for tissue-based studies of gene expression.Journal of molecular histology · 2004
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

R N RosierDepartment of Orthopaedics, University of Rochester School of Medicine, New York, USA.

L A Teot

D G Hicks

C Schwartz

R J O'Keefe

J E Puzas

Funding

GROWTH FACTORS AND EPIPHYSEAL CHONDROCYTE MATURATIONR01AR038945 · NIAMS · UNIVERSITY OF ROCHESTER · PI O'KEEFE, REGIS J. · 1994 to 2006

$2.4M

GROWTH FACTORS AND EPIPHYSEAL CHONDROCYTE MATURATIONR29AR038945 · NIAMS · UNIVERSITY OF ROCHESTER · PI ROSIER, RANDY N · 1987 to 1991

–

NCRR NIH HHS 57RRO5403-30NIAMS NIH HHS AR 38945

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Resistance, MultipleAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsATP Binding Cassette Transporter, Subfamily B, Member 1Base SequenceBlotting, NorthernBone NeoplasmsChildFemaleGene ExpressionHumansImmunohistochemistryIn Situ HybridizationMaleATP Binding Cassette Transporter, Subfamily B, Member 1Oligonucleotides, Antisense

Identifiers

PMID7634047

PMCPMC2329065

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.